Boston Scientific’s Tobin: Rising R&D Costs Leave Little Room For Small Firms
This article was originally published in The Gray Sheet
Executive Summary
The medical device industry will be dominated by an increasingly exclusive club of large, broad-based companies as the cost of innovation shuts out smaller players and fuels further consolidation, Boston Scientific CEO Jim Tobin predicts